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Studies of human brain development are critical as research on neurological disorders have been progressively advanced. However,
understanding the process of neurogenesis through analysis of the early embryo is complicated and limited by a number of factors,
includingthecomplexityoftheembryos,availability,andethicalconstrains.Theemergingofhumanembryonicstemcells(hESCs)
andinducedpluripotentstemcells(iPSCs)hasshedlightofanewapproachtostudybothearlydevelopmentanddiseasepathology.
The cells behave as precursors of all embryonic lineages; thus, they allow tracing the history from the root to individual branches
of the cell lineage tree. Systems for neural diﬀerentiation of hESCs and iPSCs have provided an experimental model that can be
used to augment in vitro studies of in vivo brain development. Interestingly, iPSCs derived from patients, containing donor genetic
background,haveoﬀeredabreakthroughapproachtostudyhumangeneticsofneurodegenerativediseases.Thispapersummarizes
the recent reports of the development of iPSCs from patients who suﬀer from neurological diseases and evaluates the feasibility
of iPSCs as a disease model. The beneﬁts and obstacles of iPSC technology are highlighted in order to raising the cautions of
misinterpretation prior to further clinical translations.
1.Introduction
Neurodegenerative and neurodevelopmental diseases are
the important causes of disability and death of humans.
Although the rapid development of novel diagnostic meth-
ods and therapeutic approaches has been in progress, there
is no emergence of an eﬃcient way to prevent and cure these
diseases. Due to the lack of a suitable disease model and an
adequate number of biopsy brain samples, the genuine etiol-
ogyandpathologyofmanynervousdiseasesareunidentiﬁed.
Transgenic animals for disease modeling were developed,
and many of them show disease pathology and response
to treatment trials. For example, the Alzheimer’s disease
(AD) mice, which overexpress familial type AD-associated
genes, amyloid precursor protein (APP), Presenilin1/2 (PS),
and Tau, show clinical pathologies of AD, such as progres-
sive memory loss, extracellular plaque, and neuroﬁbrillary
tangles [1]. Although animal model continues to produce
key insights into disease mechanisms, these systems have
limitations that could be potentially overcome by human
cellular models of diseases. Many transgenic murines do not
faithfully mirror the respective human pathophysiology. For
example, a mouse model for Down syndrome (DS) fails to
recapitulate the human cranial abnormalities, a common
associatedfeatureoftrisomy21[2].Thismaysuggestthatthe
mouse model for human trisomy 21 is not fully appropriate,
and an alternative system is necessary for exploring disease
mechanisms [3].
Human embryonic stem cells (hESCs) are isolated from
the inner cells mass of blastocyst stage embryos which can
be further diﬀerentiated into three embryonic germ layers:
ectoderm, mesoderm, and endoderm [4]. Recent results
indicate that the diﬀerentiation of hESCs in culture follows
the hierarchical sets of signals that regulate embryonic
developmentinthegenerationofthegermlayersandspeciﬁc
cell types [5]. Establishment of in vitro diﬀerentiation
systems that recapitulate normal development will form the
foundation for dissecting molecular interactions. The ability2 Journal of Biomedicine and Biotechnology
to access and manipulate populations representing early
developmental stages in the hESC diﬀerentiation cultures
provides a new approach for addressing questions of lineage
commitment, such as neurodevelopment [6]. This system
provides a model of human brain development that enables
manipulations comparable to those carried out in other
organisms such as Xenopus and zebraﬁsh, but in human
species context. In order to derive disease-speciﬁc hESCs,
there are two conventional methods which are (1) the
isolation of single blastomere from morula stage embryos
which are entered into preimplantation genetic diagnostic
(PGD) program and (2) the derivation of hESCs by somatic
c e l ln u c l e a rt r a n s f e r( S C N T )[ 7]. PGD is a clinical procedure
for screening fertilized embryos at morula stage in order
to ensure disease-free embryos [8]. The embryos that are
diagnosed as disease threatened will be either discarded or
donated for research [9]. On the other hand, SCNT is an
alternative approach to generate patient-speciﬁc hESCs. The
nucleus from the somatic donor cells is transplanted into the
enucleated oocytes by micromanipulator, leading to union
of both components [10]. However, the success rate of hESC
establishment form PGD and SCNT is considerably low and
technicaly demanding. Moreover, SCNT is limited by the
lack of oocyte donors and ethical issues; causing genomic
reprogramming by nuclear transfer has not been extensively
demonstrated in human [11–13].
Because of the multiple drawbacks of hESCs and the
derivation approaches, another pluripotent cells could be
derived from somatic cells by the forced expression of key
pluripotent transcription factors of hESCs (OCT4, c-MYC,
SOX2, and KLF4), and these cells were named as induced
pluripotent stem cells (iPSCs) [14, 15]. After the discovery
of iPSCs by Takahashi et al. in 2007 , the trend of
disease modeling has intensively focused on iPSC technology
as this technique could generate pluripotent cells from
diagnosed living patients and be further diﬀerentiated into
disease-relevant cell types for drugs screening and disease
development monitoring [16]. Thus, this paper will discuss
the current success of iPSC derivation from neurological
disease patients which will ultimately lead to an answer of
pathological causes and a novel pharmaceutical product to
treat those diseases.
2.Insights:The Propertiesand Originsof
Human Pluripotent Stem Cells
Primarily, hiPSCs have been characterized by following the
characteristics of hESCs. These two pluripotent cell types
display several similar properties, such as their morphology,
self-renewal, diﬀerentiation capacity, cell surface antigens,
and gene expression proﬁle [16]. They are immortalized cells
and could be diﬀerentiated into all primary embryonic germ
layers, including gut epithelium, cartilage, bone, smooth
muscle, striated muscle, neural epithelium, embryonic gan-
glia, and stratiﬁed squamous epithelium [17]. hESCs and
iPSCs show the high expression of telomerase reverse
transcriptase [18] as well as the stage speciﬁc embryonic
antigens (SSEAs), which are SSEA-3, SSEA-4, TRA-1-60
and TRA-1-81. Interestingly, it was demonstrated that the
expression pattern of these surface antigens is present in the
ICM of human blastocysts, providing evidence that hESCs
continue to resemble the cells in the ICM [19]. Self-renewal
and pluripotency of hESCs and iPSCs are mainly controlled
by intrinsic transcription factors. The best-studied intrinsic
factors are Oct4, Nanog, and Sox2, which play essential roles
in both mESCs and hESCs. The downregulation of these
factors leads to hESC diﬀerentiation [20–22]. The signiﬁcant
roles of these transcription factors in pluripotency have been
conﬁrmed by the ability to reprogram human ﬁbroblasts to
become pluripotent cells [16]. As exhibiting pluripotency,
when embryoid body is formed from hESCs and iPSCs,
the cell aggregates show similar structure to early stage of
human embryos which consist of all three embryonic germ
layers [23]. hESCs can also form teratomas following the
injection of cells into nude mice, which reﬂects their in vivo
diﬀerentiation capability [24, 25]. Even if hESCs have been
consideredacellresourceforregenerativemedicine,thereare
several controversial issues needed to be taken into account,
including ethical constrains of embryo destruction, graft-
versus-host disease, and the diﬃculty to obtain diseased-
speciﬁc cell lines. Since the discovery of iPSCs by using
dermalﬁbroblasts,scientistshaveextendedtovariousorigins
of starting cells such as neural stem cells [26], adipose-
derived mesenchymal stem cells [27], umbilical cord blood
[28],andT-celllymphocyte[29,30].Forthesereasons,iPSCs
are suggested to become a new paradigm for generating
patient-speciﬁc pluripotent stem cells to model neurological
genetic diseases.
3. hiPSCs Breakthrough: The Systems for
NeurologicalDiseaseModeling
In clinical research, it is hard to obtain brain tissues from
either live or dead patients for investigating diseases. This
diﬃculty has limited the knowledge of human neurolog-
ical abnormalities and pathology progression during the
course of diseases [31]. Reprogramming of somatic cells
from nervous disorder patients by using iPSC technology
has provided an opportunity to generate disease-harboring
pluripotent cells which can be diﬀerentiated into neural cells
for studying disease development. Dermal ﬁbroblast cells are
widely used as starting cells for somatic cell nuclear repro-
gramming. The diﬀerentiation propensity of iPSCs toward
speciﬁc cell types, such as neural cells, is marked by the epi-
geneticmemoryofstartingcells[32].Thecurrentestablished
iPSCs derived from neurodevelopment and neurodegenera-
tive disorder patients are summarized in Table 1, while the
similarities and diﬀerences of ESCs and iPSCs are illustrated
in Table 2. Categorizing by types of diseases, neurological
disease-speciﬁc iPSCs could be divided into two major
groupswhichareearly-onsetneurodevelopmentdiseasesand
late-onset neurodegenerative diseases. Neurodevelopment
diseases are mostly triggered by abnormal gene expression,
while neurodegenerative diseases typically resulted from
bothabnormalgeneexpressionandenvironmentfactors.Itis
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Table 1: List of reported hiPSC disease models.
Disease Target cell
Potential to be disease model
Drug test Reference
Successful diﬀerentiated
into target cell type Neuronal pathology
Early-onset neurological disorders
Fragile X syndrome ND ND Loss of FMR1
expression ND [44]
Prader-Willi syndrome Neurons Yes Imprint disorder ND [48, 65]
Rett’s syndrome Neurons Yes
Loss of synapses,
reduced spine density,
smaller soma size
Yes [31]
Familial dysautonomia Neural crest cells Yes Loss of neural crest cells Yes [54]
Friedreich’s ataxaia Motor neuron Yes FXN gene repression ND [61]
Angelman’s syndrome Neurons Yes Imprint disorder ND [65]
Down’s syndrome Neuron ND ND ND [69]
Spinal muscular atrophy Motor neurons Yes
Loss of neuron
formation, loss of SMN
gene expression
Yes [34]
Late-onset neurological disorders
Amyotrophic lateral
sclerosis (ALS) Motor neurons ND Not shown ND [38]
Huntington’s disease (HD) Striatal neurons Yes Not shown ND [37]
Parkinson’s disease (PD) Dopaminergic
neurons Yes Not shown ND [35, 36]
Alzheimer’s disease (AD) Cholinergic
neurons Yes Increase ratio of Aβ42
to Aβ40 Yes [87]
∗ND: not determined.
Table 2: Summarizing the similarities and diﬀerences of ESC and iPSC for disease modeling.
hESCs iPSCs Reference
Source ICM Adult somatic cell [4, 15]
Basic pluripotent characteristics
Alkaline phosphatase activity Yes Yes [4, 15]
Pluripotent genes expression Yes Yes [4, 15]
Pluripotent cell surface markers Yes Yes [4, 15]
In vitro and in vivo multilinage diﬀerentiation Yes Yes [4, 15]
Transcriptomic expression Normal pluripotent gene expression
Pluripotent gene expression
but not all genes similar to
hESCs and depend on
reprogramming technique
[36, 100]
Proteomic expression Normal proteomic expression
Not all proteomic
expression identical to
hESCs
[101]
Disease modeling From PGD diagnosed embryo in IVF clinic From diagnosed adult
patient somatic cell [88, 102]
Disease-related expression characteristic Yes Yes [88, 102]
since neural cells derived from iPSCs display an early stage
of disease development [31, 33]. However, immature pheno-
types of neurons derived from iPSCs hinder the applications
of modeling for late-onset diseases [33]. It is important
to note that although some neurons derived from iPSCs
predominantly exhibited disease pathology and responded
to pharmaceutical agents [31, 34, 35], a number of neural
cells from certain diseased iPSCs did not show neuronal
pathology, such as Parkinson’s disease [35, 36], Huntington’s
disease [37], and amyotrophic lateral sclerosis [38]. Speciﬁc
gene mutations or environmental stress inducers are needed
inordertoacceleratethepathologyofthosediseases[35,36].4 Journal of Biomedicine and Biotechnology
4. TheCurrentAvailableiPSCsfromMonogenic
Early-OnsetNeurological Disorders
4.1. Fragile X Syndrome. F r a g i l eX( F X )s y n d r o m ei sa n
X-linked dominant disorder which is the most common
form of inherited mental retardation [39]. The cognitive,
behavioral, and physical phenotypes vary by sex in which
males are severely aﬀected due to the X-linked inheritance
of mutation [40]. This disease caused by no expression of
the fragile X mental retardation 1 (FMR1) gene, resulting
from untranslation of CGG triplet repeat expansion in the
5  UTR region of the gene [41]. According to the loss of
FMR1 protein, developmental retardation is signiﬁcantly
found in the cerebral cortex. Quantitative examination of
human brain autopsy exhibits abnormal dendritic spine
lengths,andshapesaremoreimmaturewhencomparedwith
normal age match controls [42, 43]. Fragile X syndrome
iPSCs (FX-iPSCs) were generated from 3 FX-aﬀected males
and compared the regulation of FMR1 transcription to
human FX-ESCs. FX-iPSCs cloned demonstrated typical
characteristic of pluripotent stem cells [44]. Surprisingly,
although the mutant FMR1 gene is expressed in FX-ESCs,
FMR1 gene expression remains inactive in FX-iPSCs. In
addition, even somatic FX-ﬁbroblasts were pretreated with
demethylating agent 5-azacytidine prior to reprogramming;
FMR1 gene remained transcriptionally silent in all FX-iPSCs
clones. This hypothesized that other epigenetic mechanisms
may aﬀect the aberrant expression of FMR1 gene. This
brought the attention that the diﬀerentiation of FX-iPSCs
into neurons may not facilitate pathological study of fragile
X syndrome [44]. Further examination of multiple factors,
suchasepigeneticfactors,isrequiredinordertoimproveFX-
iPSC properties, in particular gene expression pattern [33].
4.2. Prader-Willi Syndrome (PWS). Prader-Willi syndrome
(PWS) is a neurological disorder characterized by neona-
tal hypotonia, failure to thrive, hypogonadism and short
stature, mild-to-moderate mental retardation, and compul-
sive hyperphagia in early childhood that leads to morbid
obesity [45]. PWS and AS are closely related in which the
imprinted genes on the proximal long arm of chromosome
15 are aﬀected. PWS is aﬀected by the lack of gene expression
inpaternalchromosome,15q11-q13,whilegenesinmaternal
chromosome are repressed by DNA methylation [46]. The
deﬁnition of etiology of this disease is unclear, but a
deﬁciency of the paternally expressed SNORD116 snoRNAs
can result in a PWS or PWS-like phenotypes [47]. PWS-
iPSCs were generated from ﬁbroblast of diagnosed PWS
patients by using retrovirus producing 4 exogenous tran-
scription factors. PWS-iPSCs showed positive-to-standard
hESCcharacteristics:cellsurfaceantigens,endogenoushESC
transcription factors, and teratoma formation. Moreover,
the methylation status of proximal promoter, OCT4 and
NANOG, displayed extensive DNA demethylation in PWS
iPSCs clone at a comparable level to hESCs. PWS-iPSCs
displayed a normal number of chromosomes, but DNA
segment translocation was observed from chromosome 15
to chromosome 4 [46, 48]. The expression of SNORD116
analyzed by quantitative PCR demonstrated that the high
expression of SNORD116 was observed in normal ﬁbroblast
and normal iPSCs, but PWS ﬁbroblasts and PWS-iPSCs
showed low expression [48]. It is suggested that PWS-iPSCs
did not display normal expression pattern of imprinted
genes which are crucial for disease determination [48]. The
results supported the hypothesis that genomic imprinting is
not susceptible to nuclear reprogramming and refractory to
acquired de novo alteration.
4.3. Rett’s Syndrome. Rett’s syndrome is an inherited neu-
rological developmental disorder which is associated with
X-linked gene inheritance encoding methyl-CpG-binding
protein 2 (MeCP2) [49]. MeCP2 is located in the nucleus of
many types of CNS neurons and functions as a transcrip-
tional repressor by associating with chromatin remodeling
complexes [50]. This disease is characterized by a variety
of clinical manifestations, indicating developmental arrest
and psychomotor repression. The patients have mental
retardation, epilepsy, respiratory dysfunction, stereotypic
hand movement, growth retardation, scoliosis, and spasticity
[51]. RTT-iPSCs were generated from four distinct MeCP2
mutation ﬁbroblasts, using retroviral reprogramming vec-
tors. The resulting cells were pluripotent as WT-iPSCs.
Immunocytochemistry results against trimethylated histone
3lysine27(m3H3K27)werepositivelymarkedatthenucleus
of some, but not all, undiﬀerentiated RTT-iPSCs, similar to
the control hESCs. This showed that the memory of the
previous chromatin inactivation state had been erased. By
immunostaining, RTT ﬁbroblasts and RTT-iPSCs-derived
neuronal population reduced MeCP2 protein levels. More-
over, the half reduction of MeCP2 protein is consistent with
the random X-inactivation. It was noted that X-inactivation
was reset in RTT-iPSCs and restored randomly during
neuronaldiﬀerentiation.ThiscausedthevariationofMeCP2
protein level, reminiscent of the brain of RTT patients
[31]. After 8 weeks of neural diﬀerentiation, the number of
VGLUT-positive glutamatergic neurons from RTT-iPSCs was
less than that derived from either to WT-iPSCs or hESCs.
ThisphenotypecouldbefoundwhentheWT-iPSCsknocked
down the expression of MeCP2, while the overexpression
of MeCP2 could increase the number of VGLUT1-positive
neurons derived from RTT-iPSCs. Morphological analysis of
RTT neurons demonstrated that the number of spine of RTT
neuritis and cell soma sizes was reduced when compared to
WT neurons. Interestingly, high concentration of aminogly-
coside antibiotic, such as gentamicin, could increase MeCP2
protein and, consequently, the number of glutamatergic
neurons [31]. This result suggested that RTT-iPSCs were
providingtheexcellentdiseasemodelingforRETTsyndrome
and could conﬁrm the pathology of the disease.
4.4. Familial Dysautonomia. Familial dysautonomia (FD)
or Riley Day Syndrome is an autosomal recessive disor-
der, characterized by the developmental loss of neurons from
the sensory and autonomic nervous system [49, 50]. FD is
caused by the mutation in a splice site of the I-kB kinase
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tissue-speciﬁc exon skipping and expression of a truncated
mRNA transcript [52]. Reduced levels of normal IKAP
protein are associated with a defect in cell motility [53]. FD-
iPSCs were generated from 10-year-old female FD patients
using lentiviral vector encoding 4 classical vectors [16].
Genetic defect, homozygous 2507+6T>C, was conﬁrmed
in FD-iPSCs by sequencing and IKBKAP analysis using
RT-PCR. Gene expression proﬁle of neural crest derived
from FD-iPSCs showed that, among the 20 most deceased
transcripts in FD neural crest precursors, many genes were
involved in peripheral neurogenesis and neural diﬀeren-
tiation. Moreover, the number of paxillin-positive cells
was reduced in FD-iPSCs-derived neural crest progenitors,
referring to the aberration of cell spreading and migration
[54]. They have reported that plant hormone kinetin could
reduce the levels of the mutant IKBKAP splice in FD
cells [54–56]. Epigallocatechin gallate and tocotrinal were
exposed to FD-iPSCs-derived neural crest precursors and
showed dramatic reduction of the mutant IKBKAP splice
form; however, the hormone did not show a signiﬁcant
increase in the expression of neurogenic markers or improve
the migration behavior [54].
4.5. Friedreich’s Ataxia. Friedreich’s ataxia (FRDA), the most
common inherited ataxia, is associated with a mutation of
the frataxin gene on chromosome 9 [57, 58]. The incidence
of mutations was often found in an unstable expansion of
GAA repeats in the ﬁrst intron. The level of GAA repeats is
correlated with the downregulation of gene expression and
the progression of disease severity [58]. The cardinal features
ofFRDAareataxiaofallfourlimbs,cerebelladysarthria,lack
of reﬂexes, sensory loss, and pyramidal signs. In addition,
frataxin insuﬃciency leaded to skeletal deformities, cardi-
omyopathy, and the risk of diabetes [57, 58]. Although
mice models of this disease are available, they do not fully
recapitulategenesilencingandfrataxinproteinlevel[59,60].
FRDA-iPSCs were established by retroviral transduction
with 4 classical transcription factors [61] and showed
typical characteristics of pluripotent cells as well as retaining
the marked repression of FXN mRNA. FRDA-iPSCs still
repeated the GAA expansion in both parental pathogenic
alleles. Furthermore, GAA repeat lengths in FRDA-iPSCs
change overtime in culture. The role of mismatch repair
(MMR) enzyme MSH2 was investigated in FRDA-iPSCs.
mRNA expression and western blotting analysis of FRDA-
iPSCs showed large increases in MSH2 level when compared
with donor ﬁbroblast. The FRDA-iPSCs have been expected
to provide a valuable modeling to study repeat instability
mechanism [61]. Diﬀerentiations to disease-speciﬁc cell
types, such as neurons, cardiomyocytes, and pancreatic
beta cells, for studing eﬀect of abnormality are required.
Moreover, the novel drugs or therapeutic protocols are ex-
pected to develop by using this FRDA-iPSCs modeling.
4.6. Angelman’s Syndrome. Angelman’s syndrome (AS) is
clinically delineated by the combination of seizure, absent
speech,andhypermotoricandataxicmovements[62,63].AS
patients exhibit a predisposition toward apparent happiness
and paroxysms of laughter, and this ﬁnding helps to distin-
guish AS from others involving severe developmental handi-
cap [63]. AS is a severe genetic disorder, caused by mutation
or deletion of the maternally inherited UBE3A gene in
chromosome 15. This gene encodes an HECT (homologous
to E6-associated protein C terminal) domain E3 ubiquitin
ligase [62]. The combination of epigenetic silencing of pater-
nal allele and gene inactivation of maternal allele of UBE3A
leads to chieﬂy incomplete loss of UBE3A protein selectively
in most neurons in the brain [64]. Recently, AS-iPSCs
lines were established from ﬁbroblasts of two AS patients,
who carried maternally inherited deletions of chromosome
15q11-q13 [65]. The methylation imprinting was assessed
and showed similar patterns to patient’s ﬁbroblasts. Only an
unmethylatedpaternalallelewasobservedinAS-iPSCs.Neu-
rons and astrocytes derived from AS-iPSCs were matured in
vitro and exhibited train of action potential and excitatory
postsynaptic current. The levels of UBE3A expression were
signiﬁcantly reduced in both of AS-iPSCs- and AS-iPSCs-
derived neurons, while normal iPSCs or iPSCs-derived
neurons maintain the level of UBE3A. There is evidence
suggesting that brain-speciﬁc UBE3A repression is mediated
by a snoRNA [47, 66, 67]. Northern blot hybridization used
to assess expression of snoRNAs, SNORD 116 and SNORD
115, demonstrated that SNORD 116 is expressed in both
iPSCs and iPSC-derived neurons derived from normal or
AS individuals, whereas SNORD115 expression is restricted
to iPSC-derived neurons. It is suggested that the neuron-
speciﬁc repression of UBE3A may occur relatively late during
neurogenesis, coincident with the upregulation of SNORD
116 and SNORD115 during neural diﬀerentiation. This
ﬁnding proposed that the methylation imprinting is diﬃcult
to be reprogrammed, and the epigenetic status is resistant to
a global erasure [65]. This AS-iPSC model recapitulates the
tissue-speciﬁcpatternofUBE3Aimprinting;thus,itprovides
an important tool to address the timing and mechanisms
controlling epigenetic status of UBE3A during human neural
development. In addition, AS-iPSCs-derived neurons will
also be a useful system for the characterization of the physi-
ological abnormalities of the disease at a cellular level [65].
4.7. Down’s Syndrome. Down’s syndrome (DS) is a devel-
opmental disorder, caused by trisomy of chromosome 21.
The key manifestations of the disease are mental retardation,
craniofacial abnormalities, and clinical defections of several
systems such as heart, gut, and immune system [68].
However, the trisomy of chromosome 21 in mice did not
result in disease symptoms which means that mouse is not
a suitable system to model AD pathology [2]. DS-iPSCs were
established from DS patient ﬁbroblasts by using either four
(Oct4, SOX2, KLF4,a n dc-MYC), or three (without c-MYC)
reprogrammingfactors.DS-iPSCsshowedthecharacteristics
of trisomy 21 anomaly by chromosomal G-banding analysis,
butnoneofdiﬀerentiationstudieshavebeenconducted[69].
DS-iPSCs are not only attractive for the investigation of
DS development, but also interesting for other DS-related
diseases such as AD, which is a frequently coincident disease
in DS patients.6 Journal of Biomedicine and Biotechnology
4.8. Spinal Muscular Atrophy. Spinal muscular atrophy
(SMA), an autosomal recessive disease, is one of the leading
genetic causes of infant mortality due to the speciﬁc loss
of alpha motor neurons in the spinal cord [70, 71].
Clinically, SMA is caused by the homozygous deletion of
survivor motor neuron 1 and 2 (SMN1 and SMN2), and the
disease severity spans a broad spectrum, based on the onset
period [71]. SMN2-derived pre-mRNA transcripts could be
alternatively spliced, causing a single nucleotide diﬀerence,
a silent cytosine-to-thymine (C-T) transition within exon
7, from the normal mRNA. This single nucleotide change
restricts the length of SMN2 protein and translates to a
dysfunction protein, named SMN Δ7. Patients with high
copy number of SMN2 producing more full length of SMN
by SMN2, are observed in milder form of the disease [72].
SMA-iPSCs were established from a type I SMA patient
and his unaﬀected mother. iPSCs were generated from
primary ﬁbroblasts with lentiviral constructs encoding Oct4,
SOX2, NANOG,a n dLIN28. SMA-iPSCs showed pluripotent
characteristics like hESCs and were not diﬀerent from WT-
iPSCs. iPSC and ﬁbroblast SMN RNA were analyzed. RT-
PCR analysis showed that SMA-iPSCs and SMN ﬁbroblast
have lower levels of SMN RNA than WT-iPSCs and WT
ﬁbroblast. Moreover, qRT-PCR result conﬁrmed the signiﬁ-
cantly reduced level of full-length SMN transcript in SMA-
iPSCs, 32–39% reduction compared to wild type. SMA-
iPSCs were diﬀerentiated into motor neurons which are
pathological speciﬁc cell types. Interestingly, motor neurons
derived from SMA-iPSCs group showed signiﬁcantly fewer
number and reduced size than motor neurons derived from
WT-iPSCs. However, there was no diﬀerence in total number
of Tuj1-positive neurons in either WT or SMA groups. This
result suggested that SMA has a speciﬁc inﬂuence on motor
neuron, and the disease phenotype selectively hinders motor
neuron production and/or increases motor neuron degener-
ation at latertime point. Neuron and astrocytes derived from
SMA-iPSCs signiﬁcantly increased the level of intranuclear
gems, intranuclear form of aggregated SMN protein, after
valproic acid and tobramycin, when compared to untreated
group [34]. The results indicated that neural cells derived
fromSMA-iPSCsrespondedtodrugscreeningandareableto
beusedasthediseasemodel forfurtherdisease investigation.
5. The Established iPSCs for the Polygenic
Late-OnsetNeurologicalDisorders
5.1. Amyotrophic Lateral Sclerosis. Amyotrophic lateral scle-
rosis (ALS) is a progressive disease, characterized by the
degeneration of upper, in layer V of the motor cortex, and
lowermotorneurons,brainstem,andanteriorhornofspinal
cord. The loss of motor neurons, especially in spinal cord,
leadstoprogressiveparalysisanddenervationatrophyofstri-
ated muscles [73]. Inheritance in familial ALS (FALS) is typ-
ically autosomal dominant [74]. The mutation in only one
gene, named Cu/Zn superoxide dismutase (SOD1), results in
classical inherited ALS [75]. iPSCs were developed by using
skin ﬁbroblasts from 82- and 89-year-old FALS patients,
who are heterozygous of the rare L144F (Leu144 →Phe)
dominant allele of SOD1. FALS-iPSCs showed normal char-
acteristic of pluripotent stem cell like hESCs. FALS-iPSCs
were diﬀerentiated to mature motor neurons, HB9 and
ISLET1/2-positive cells, astrocytes, and GFAP-positive cells.
The abnormality of motor neurons and diﬀerentiated cells
from FALS-iPSCs has been described [38]. Thus, the expres-
sions of disease characteristics as well as the pathological
anomaly of motor neuron needed further investigations,
such as persistent of SOD1 mutation in developed iPSCs.
5.2.Huntington’sDisease. Huntington’sdisease(HD)ischar-
acterized by the loss of brain striatal neurons that results
from the expansion of a CAG repeat, translated into glu-
tamine and produced mutant huntingtin protein [76]. The
pathological change in HD brain is evident by the massive
loss of medium spiny neurons (MSNs) in the striatum and
loss of neurons in the cortex which results in chorea, demen-
tia, and eventually death [77]. HD-iPSCs line was made
from HD patients with 72 repeat CAG nucleotides [37, 69].
Every cell derived from HD-iPSCs, including HD-NSCs and
striatal diﬀerentiated neurons, contained 72 CAG repeats.
HD neural stem cells (HD-NSCs) and striatal neurons could
be generated from these HD-iPSCs, but the population of
striatal neurons, DARPP-32-positive cells, were dramatically
low,approximately10%ofthetotalneurons.Caspaseactivity
was evaluated after the withdrawal of growth factors for 24
hours. In HD-NSCs, caspase 3/7 activity was stimulated, but
not in WT-NSCs [37]. This suggested that HD-iPSCs and
their diﬀerentiated striatal neurons are a suitable model for
HD, and this could be further supported by the comparison
with another alternative system in nonhuman primate ESCs
[78]. However, the level of huntingtin protein in HD-iPSCs
has not yet been demonstrated.
5.3. Parkinson’s Disease. Parkinson’s disease is the second
most common neurodegenerative disease after Alzheimer’s
disease [79]. Currently, there have been identiﬁed 6 causative
genes in which their mutations are associated with the
high incidence of PD. These six genes include α-synuclein,
parkin, UCH-LI, PINK1, DJ-1, and LRRK2/dardarin [80].
The manifestations of PD are resting tremor, bradykinesia,
rigidity, and gait impairment. The motion diﬃculty of PD
patients is attributed to the loss of dopaminergic (DA)
neurons within the substantia nigra (SN), causing the
dysfunction of the basal ganglia. The motor symptoms and
survival rate of PD patients could be relieved by synthetic
dopamine replacement [81]. PD-iPSCs were generated from
idiopathic PD patients with either 3 (without c-Myc) or 4
transcription factors by using lentivirus ﬂanked with loxP
sites. Thus, these exogenous genes could be later removed
by Cre recombinase in order to fabricate the factor-free PD-
iPSCs. Not only establishing the pluripotent state, the factor-
free PD-iPSCs also showed a close global gene expression
proﬁle to hESCs. DA neurons could be generated from PD-
iPSCs at a comparable eﬃciency to non-PD-iPSCs or hESCs
[36]. This was suggested due to the short time span of
cultured neurons since the onset period of PD patients is
approximately over 50 years old. In order to accelerate theJournal of Biomedicine and Biotechnology 7
diseasepathology,theexogenousstimuli,suchasanexposure
to oxidative stress, neurotoxin, or overexpression of PD-
related genes (α-synuclein or LRRK2), may be needed to
supplement the culture systems [36]. On the other hand,
ﬁbroblasts from monogenic mutation of PD were also repro-
grammed to iPSC state. These ﬁbroblasts carried p.G2019S
mutation (called G2019S-iPSCs) in the leucine-rich repeat
kinese-2 (LRRK2) which is the most common PD-related
mutation [35]. DA neurons derived from G2019S-iPSCs
showed not only the increased expression of key oxidative
stress-response gene and α-synuclein protein, but also the
highsensitivitytocaspase3activationandcell-death-causing
agents. Moreover, the treatment of cell death inhibitor,
ROCK inhibitor, or Y-27632, did not protect G2019S-iPSC-
derived DA neurons from hydrogen peroxide or MG-132-
mediated caspase 3 activation [35]. The results emphasized
the possibility to generate the late-onset neurodegenerative
disease models by using disease-related exogenous stimuli
and mutant cell lines. However, the solid protocol of disease-
speciﬁc cell type diﬀerentiation and long period maintaining
diﬀerentiated cell in vitro are needed to develop further
investigation.
5.4. Alzheimer’s Disease (AD). Alzheimer’s disease (AD) is
known as the most common neurodegenerative disorder in
aged people. The AD’s patients show progressive memory
retardation and cognition disturbance. The pathology of
this disease is neuronal loss in the cerebral cortex accom-
panied by massive accumulation of amyloid ﬁbril forming
senile plaque and hyperphosphorylated tua protein forming
neuroﬁbrillary tangle (NFT) [82]. The amyloid ﬁbril is
mainly composed of β-amyloid (Aβ) peptide, the 40 and 42
amino acid form (Aβ40 and Aβ42), which is derived from
proteolytic cleavage from the amyloid precursor protein
(APP) by β-a n dγ-secretase enzyme activity [83–85].
Accumulation of Aβ plaque, mainly Aβ42, in the brain
parenchyma is the initiation of AD pathogenesis and it leads
to the formation of NFT which enhances degeneration of
neurons [84]. Presenilin 1(PS1) and presenilin 2 (PS2) genes
encode the major component of γ-secretase which mutated
in autosomal-dominant familial Alzheimer’s disease [86].
Mutation in the PS1, PS2,a n dAPP g e n e si sr e p o r t e dt h e
most of familial early-onset cases of AD with high level
of Aβ42 production and greater ﬁbrillary amyloid deposits
[86]. Recently, iPSCs from ﬁbroblasts of FAD with the
PS1 mutation A246E and the PS2 mutation N141I were
established by retrovirus transduction with the ﬁve factors
Oct4, SOX2, Klf4, LIN28,a n dNANOG [87]. All PS1 and
PS2 iPSC clones demonstrated typical characteristics of
pluripotent cell when compared with both normal 201B7
iPSC line [15] and the sporadic PD-derived iPSC line which
was reprogrammed by the original methods [15]. Both PS1
and PS2 lines were induced to diﬀerentiate into neurons.
Comparingwithanormalcontrol,theyshowednodiﬀerence
of the eﬃciency to generate neurons; however, the ratio of
Aβ42 to Aβ40 was signiﬁcantly elevated in PS1 and PS2
iPSCs-derived neurons. Surprisingly, neither abnormal tau
protein accumulation nor tangle formation was detected
in FAD-derived neurons. This may result from the short
culture period (2 weeks) for tauopathy formation. Not only
produced the Aβ which is the pathological hallmark of AD,
FAD-derivedneuronsalsorespondedtoγ-secretaseinhibitor
(compound E) and γ-secretase modulator (compound W)
i no r d e rt od e c r e a s et h er a t i oo fA β42 to Aβ40. These data
highlighted that both PS1 and PS2 iPSC-derived neurons
respond to drug treatment as expected and could be useful
for a novel drug screening for AD treatment [87]. Neverthe-
less, neural speciﬁc diﬀerentiation protocol and long-term
culture methods of mature neurons are necessary to enhance
dominant disease pathologies.
6.The Perspectivesof DiseaseModeling
by HumanInducedPluripotentCells
One of the most interesting aspects of iPSC technology is the
possibility to develop autologous cells for cell replacement
therapy.Thepatient-speciﬁcpluripotentcellscouldbediﬀer-
entiated into desired cell types in the unlimited cell number
manner which, ultimately, could be transplanted into the
patient’s own body. However, techniques of reprogramming
somatic cells are necessary to be nonviral, nononcogenic,
and nongenetic modiﬁcation. Moreover, diseases which are
related to imprinting genes and epigenetic anomaly, such
as FX [44], AS [65], and PWS [48, 65]a r ed i ﬃcult to
be completely reprogrammed and reset their epigenetic
memory [32], which means iPSC technology needs further
development in order to overcome these issues. Importantly,
the diﬀerentiation protocols of desired cell types must be
robust and eﬃcientinordertoproducehighpuriﬁedspeciﬁc
cell types. For these reasons, the use of iPSCs for cell
replacement therapy is not yet ready for clinical applications
at this moment [88].
The other applications of iPSCs are the generation
of pluripotent cells from developmental or degenerative
disorder patients for disease modeling and drug discovery.
According to the lack of ideal animal models and inaccessi-
bility to biopsy brain samples from live patients, generation
of human pluripotent stem cells has opened an opportunity
to investigate disease development in vitro [31]. Ultimately,
if iPSCs could be generated in individualized manner, the
most eﬀective drug for each patient could be validated
[33, 89]. To date, there are 4 technical challenges if we
want to use iPSCs as a disease model. Firstly, the transgene-
free iPSCs should be produced in order to minimize or
eliminate genetic alterations in the derived iPSC lines. It
has been reported that the gene expression features of
factor-free PD-iPSCs were closely similar to hESCs [36].
There are many other factor-free methods available for iPSC
establishment, such as episomal vector [90, 91], synthetic-
modiﬁed mRNAs [92], recombinant proteins [93, 94], or
miRNA [95, 96]. Secondly, the solid diﬀerentiation protocols
of iPSCs into disease-speciﬁc cell types must be robust and
eﬃcient [35, 87]. The production of speciﬁc cell type in a
clinical scale is very diﬃcult, resulting from a short time
span of cells in culture conditions. Moreover, speciﬁc cell-
sorting methods have to be developed for purifying only8 Journal of Biomedicine and Biotechnology
disease-related cell types for further investigation. Thirdly,
the in vitro disease-relevant phenotypes must be formed.
The most important feature for disease-modeling system is
the appearance of disease phenotype; however, some of the
neural cells derived from patient iPSCs do not show clinical
disease phenotypes after the diﬀerentiation [36, 44, 69], in
particular iPSCs derived from neurodegenerative diseases
with long latency, such as Parkinson’s and Huntington
diseases. The possibility to overcome this challenge would
be the attempt to accelerate the appearance of pathological
phenotypes by the exposure of disease stimulators eﬀects,
such as oxidative stressors, hydrogen peroxide, or MG-132
[35, 36, 87]. Lastly, the disease-relevant phenotypes could
be generated by human-animal chimeras. Some diseases may
not be practical to in vitro model since the pathological onset
appears in elderly patients with complex pathophysiology.
Chimerasprovidelong-termaccesstocomplexandchanging
environmental context for hiPSCs. Many types of late-
onset diseases, such as Alzheimer’s and Parkinson’s diseases,
are multifactorial disorders, caused by both genetic and
environmental factors. These chimeric animals will provide
the in vivo model for long-term modeling in various types of
environmentalfactorswhichwillprovidetheclosesystemsto
human diseases [97, 98], such as triple knockout of amyloid
precursor protein (APP), APLP1, and APLP2 chimeric mice
which show a mixed population of triple knockout APP
neuron in WT back ground brain [99]. In conclusion, the
iPSC technology is the powerful technique which allows
scientists to investigate the neurological disease development
and screen pharmaceutical compounds. Several diseases
of the nervous system remain to develop disease-speciﬁc
iPSCs. In the near future, iPSC technology will facilitate
stem cell biologists and neuroscientists to unravel disease
mechanisms and discover the new therapeutic approaches
for neurological disorders.
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